Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

NCT05534789

TerminatedN/A

Sponsor: Pfizer

Conditions: Carcinoma, Renal Cell

Countries: United States

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Participants diagnosed with locally advanced or metastatic renal cell carcinoma
* Participants with full medical information is available regarding all treatments before, during and after 1st line

Exclusion Criteria:
Locations (1)
  • New York, New York, United States